Question 1

How safe is AOD-9604 to use?

Accepted Answer

Nobody can give that answer from the published record, because the record holds no measurement of harm in a person. What it holds is a hope written in 2000. The rat paper that launched the compound ended by suggesting it may have the potential to be developed into an orally usable and safe therapeutic agent for obesity. That sentence was a plan for future trials, and it rested on obese rats followed for less than three weeks. Twenty-six years later, a sports medicine review covering AOD-9604 by name concluded that rigorous human safety data are scarce, and there is potential for serious harm to patients. Read those two sentences together. The first is an early guess from a short animal study, and the second is a verdict on the whole field after the trials failed to report. Neither one is a measured finding about AOD-9604 in a person, which is the thing a reader asking this question actually wants, and that gap is the honest answer rather than a dodge.

Question 2

What are the potential side effects of AOD-9604 injections?

Accepted Answer

No study we cite lists side effects from injecting AOD-9604 under the skin of a person. The injection record that exists belongs to rabbits, and the needle went into the knee. In that 2015 study, mature New Zealand white rabbits (n=32) were randomly administered 2 mg collagenase type II twice in each knee joint, to damage the cartilage on purpose. The researchers then gave weekly injections into the joint for 4-7 weeks, and scored cartilage damage and lameness at 8 weeks. The abstract reports joint scores rather than a list of harms, so it cannot say whether anything went wrong at the site. For the injected growth-hormone peptides as a group, a 2026 review lists injection-site reactions among the reported adverse effects. That line describes a class of compounds rather than this one, and it is the nearest thing to an answer the literature offers.

Question 3

What side effects are reported for peptides like AOD-9604?

Accepted Answer

The list most people repeat comes from reviews of a whole family of compounds, and it is worth knowing where it ends. A 2026 endocrinology review covering AOD9604 alongside growth hormone releasing peptides writes that reported adverse effects span endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetite changes, and dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions. In plain terms, that covers hormone and blood-sugar upsets, water retention, and aching muscles and joints. Most of the compounds in that review work by pushing the body to release more growth hormone, and several of those effects are what extra growth hormone is known to cause. AOD-9604 was designed to keep only the fat-releasing piece of the hormone, so the list may fit it badly in either direction. That is the limit of a class list. It tells a reader what to watch for across the family rather than what this fragment was shown to do, and the study that would separate the two has not been published.

Question 4

How long does the human safety record for AOD-9604 run?

Accepted Answer

It has a start date and no end, because the trials that began never published an outcome we could find. A 2004 industry note records that Metabolic is developing AOD-9604 for the potential treatment of obesity, and that by February 2002, phase IIa trials were underway. A 2006 review still listed it in the present tense, saying drugs that improve adipose tissue function or fatty acid metabolism (e.g., AOD9604) also are in clinical trials. A phase IIa trial is a small early study, and it normally reports the side effects it saw. None of that reporting reached the journals in the research behind this page. So the longest exposure with a published outcome is still the rat work, at 19 days of daily oral dosing. A safety record measured in days, in rodents, says nothing about months of use in people. That is not the same as a clean result.

Question 5

Can AOD-9604 cause cell growth or cancer?

Accepted Answer

This is the worry that follows anything made from growth hormone, and one experiment tested the part of it that can be tested in a dish. A 2001 mouse study used BaF-BO3 cells transfected with the hGH receptor to measure in vitro 125I-hGH receptor binding and cell proliferation, meaning cells built to divide when growth hormone reaches them. The result separated the two molecules: AOD9604 does not compete for the hGH receptor and nor does it induce cell proliferation, unlike hGH. A 2026 review still flags biologically plausible but unproven mitogenic concerns across this class, mitogenic meaning able to drive cell division. Weigh what the cell test covers. It shows the fragment did not act through one receptor in one engineered cell line. It does not establish anything about tumours, which take years to appear and which no study we cite followed anyone long enough to see.

Question 6

Is it safe to take AOD-9604 every day?

Accepted Answer

Daily dosing has been studied in one species, for under three weeks, and the outcome was about weight rather than harm. In obese Zucker rats, daily oral dosing for 19 days reduced over 50% body weight gain of the animals in comparison with the control. The same rats showed no adverse effect on insulin sensitivity, as demonstrated with euglycemic clamp techniques, the laboratory method for measuring how well insulin works. The mouse work used steady delivery instead: obese and lean mice were treated with hGH, AOD or saline for 14 days using mini-osmotic pumps. Those are the only repeated exposures with results. Nineteen days in a rat bred to gain weight is a different question from months of daily injections in a person, and no study in the research behind this page has asked the second one. The amounts used in each experiment are set out on the AOD-9604 dosage page.

Question 7

Who was excluded from the AOD-9604 studies?

Accepted Answer

No human trial with a published method exists among these sources, so there is no exclusion list to read. The animal studies show who was chosen instead, and that choice shapes everything else on this page. The rat work used obese Zucker rats, a strain bred to put on weight. The mouse work used obese (ob/ob) and lean C57BL/6J mice, two genetic lines picked to contrast fat and lean animals. That means the people a reader would most want covered are absent from every result: anyone pregnant, anyone with diabetes, anyone on other medicines, and anyone older or with heart or kidney disease. Their absence is not a finding that the compound harms them. It means the question was never put, which is a different situation from one where it was put and the answer came back clean.

Question 8

What does AOD-9604 interact with?

Accepted Answer

No interaction study appears among the sources behind this page. The one combination with a published result was deliberate, and it was in rabbit knees. In that study, the group given AOD-9604 together with hyaluronic acid, a joint lubricant, had a lameness period that was significantly shorter than those in Groups 1, 2, and 3. That is a pairing that helped a damaged joint, rather than a test of whether two compounds clash. The interaction worry in the clinical literature is about stacking. A 2026 review names uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains as a reason clinicians need a framework for these patients. Stacking means taking several compounds at once, often other growth-hormone peptides. When something goes wrong in a stack, nobody can tell which part caused it, and that is why the absence of interaction data matters more here than it would for a compound taken alone.

Question 9

Is AOD-9604 hard on the liver or kidneys?

Accepted Answer

No study we cite measured liver or kidney function after AOD-9604, in any species. The rodent papers recorded weight, fat burning and blood sugar, and stopped there. The 2001 mouse study lists exactly what it took: body weight, caloric intake, resting energy expenditure, fat oxidation, glucose oxidation, and plasma glucose, insulin and glycerol were measured before and after treatment. There is no liver enzyme or kidney marker on that list. A 2026 endocrinology review written for doctors frames the job as helping clinicians interpret symptoms and laboratory abnormalities in patients using these compounds. That framework does not tell a reader what AOD-9604 does to an organ. A blood test taken after use can be read against normal ranges, but what an abnormal result would mean for this compound has not been studied, and a normal result does not cover what a test did not measure.

Question 10

What regulatory actions have touched AOD-9604?

Accepted Answer

The actions on record come from customs and anti-doping work rather than from a medicines regulator weighing an application. A 2014 paper reports the identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities, with AOD9604 as its case. A 2015 paper adds that the peptide is available on several Internet websites and was recently identified in confiscated vials in the USA. The same paper states that AOD9604 may be used as a performance enhancing drug and is banned by the World Anti-doping Agency (WADA). A seizure is a finding about a supply chain rather than about the molecule. It says material was moving outside any approved route, which is why the contents of a vial matter as much as the compound named on it. Whether it is legal and what the sport ban covers are taken up on the AOD-9604 overview.

Question 11

Does the vial itself carry risk the compound does not?

Accepted Answer

For a compound with no approved maker, the vial is often the larger unknown. A 2026 sports medicine review describes a parallel "gray market" of unapproved compounds operating largely outside of regulatory oversight, and names AOD-9604 among the peptides it covers. Outside that oversight, nobody checks that a vial is sterile, that it holds the stated amount, or that it holds the right peptide at all. Doping chemists have written about the inventiveness and, at the same time, unscrupulousness of black-market (designer) drug producers and providers in this field. None of those risks belongs to AOD-9604 as a molecule. A contaminated vial would cause harm whatever name was printed on it, and a clean rodent record says nothing about what was dissolved in that vial. How to check a vial is set out on the AOD-9604 sourcing page.

Question 12

What do doctors look for in someone using AOD-9604?

Accepted Answer

The most useful safety writing on this compound is aimed at doctors, and it is careful about what it does not claim. A 2026 review proposes a clinically oriented assessment algorithm to support exposure history taking, triage of symptom domains, and risk communication without legitimising off-label peptide regimens. In plain words, that means asking what was taken, how much of it, for how long, and with what else, then sorting the symptoms by body system. The same review pays particular attention to hormonal imbalance, endocrine-metabolic risk, and biologically plausible but unproven mitogenic concerns. A second 2026 review adds that it discusses the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect. That pairing is worth noticing. The same writers who ask doctors to look hard for harm also warn that what people feel may come from what they expect, and that cuts both ways for any report a reader sees online.

Question 13

Why is the AOD-9604 harm record this thin?

Accepted Answer

Because the compound left drug development before the stage that produces a harm record, and the published trail stopped with it. A 2006 review of obesity compounds in development noted that of these, only rimonabant has got as far as completing phase III clinical trials. Phase III trials are the large ones, and they are where most side-effect data comes from. Compare what a 2007 review could say about rimonabant, which reached that stage: it improves glycemic and lipid profiles, but it induces anxiety and depressive disorders. The same review lists AOD-9604 only by name, under others, as a human growth hormone fragment (AOD9604). That contrast is the whole explanation. A compound that reaches large trials gets a list of harms, while one that stops earlier gets a line in a table. The thin record describes how far testing went rather than how the compound behaves.

AOD-9604 side effects and safety data